Peregrine Pharma shares skyrocket; Roche chairman sours on Illumina bid;

 @FierceBiotech: Indian supreme court: Unregulated trials causing 'havoc'. More | Follow @FierceBiotech

@JohnCFierce: As Big Pharma falters, Big Biotech helps fill a $100B "gap." Editor's Corner | Follow @JohnCFierce

@RyanMFierce: Boehringer doesn't want $LLY's basal insulin analog anymore, amends big diabetes pact. News | Follow @RyanMFierce

> Roche's ($RHHBY) chairman shot down chances of his company mounting another effort to acquire Illumina ($ILMN). Item

> Peregrine Pharmaceuticals ($PPHM) shares soared more than 60% on Monday on the back of news that its review of data from a midstage study of its candidate bavituximab in patients with non-small cell lung cancer has encouraged the company to advance the drug into Phase III development. Item

> Merck ($MRK) says that the FDA has accepted its resubmitted NDA for its contender called sugammadex for reversing neuromuscular blockade. Item

> Vertex ($VRTX) updated on key programs in hepatitis C and cystic fibrosis and plans for 2013. Release

Medical Device News

 @FierceMedDev: Johnson & Johnson's first vaginal mesh trial revs up this week. More | | Follow @FierceMedDev

@MarkHFierce: Illumina is grabbing Verinata Health for $350M-plus. The buy gets it into fetal Dx business. Story | Follow @MarkHFierce

 @DamianFierce: Unregulated clinical trials are wreaking "havoc" in India, the supreme court says. News | Follow @DamianFierce

> SeraCare refocuses energies on in vitro Dx work. Item

> EndoChoice grabs $45M to back merger with Israeli GI startup. Story

Pharma News

@FiercePharma: Eli Lilly's 2013 profits forecast surpasses analyst predictions. What gives? More | Follow @FiercePharma

 @AlisonBFierce: What's the buzz? Big Pharma may be on the verge of a buying spree. News | Follow @AlisonBFierce

> Roche chairman pooh-poohs another Illumina bid. Report

> Valeant chief shoots for $10B in sales--and then $20B. Story

Biotech IT News

> Quants collaborate on forecasting value of genomics in medicine. Story

> Is FDA keeping social media from taking flight in pharma? Editor's Corner

> Abbott spinoff AbbVie starts social media effort from scratch. Article

> Agilent unit picks up lab software rights to fuel cancer diagnostics biz. News

CRO News

> WCCT partners with U.S.'s largest trial registry on patient adherence. Article

> Questcor snags CMO BioVectra for $50.7M. News

> Cellular Dynamics signs on with AstraZeneca for drug discovery. Story

> Indian Supreme Court: Unregulated trials causing 'havoc'. Report

> Clinical Network Services buys CRO Beltas. Item

And Finally… Health insurers, not as much the FDA, give biotech chiefs the jitters. Column